Universal-Beteiligungs- und Servicegesellschaft’s Aktis Oncology AKTS Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$254K	Buy	+14,185	New	+$275K	﹤0.01%	1920

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's AKTS Position: Q1 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft opened a new position in Aktis Oncology (AKTS) in Q1 2026: 14,185 shares worth $254K. The stake represents ﹤0.01% of the portfolio and ranks #1920 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

Universal-Beteiligungs- und Servicegesellschaft held 14,185 shares of Aktis Oncology worth $254K as of Q1 2026.
Aktis Oncology was a new Universal-Beteiligungs- und Servicegesellschaft position in Q1 2026.
Aktis Oncology made up ﹤0.01% of Universal-Beteiligungs- und Servicegesellschaft's portfolio in Q1 2026, its #1920 holding.
69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q1 2026, filed 11 May 2026.